Accessibility Menu
 
Acumen Pharmaceuticals logo

Acumen Pharmaceuticals

(NASDAQ) ABOS

Current Price$2.69
Market Cap$194.25M
Since IPO (2021)-86%
5 YearN/A
1 Year+174%
1 Month-13%

Acumen Pharmaceuticals Financials at a Glance

Market Cap

$194.25M

Revenue (TTM)

$0.00

Net Income (TTM)

$121.33M

EPS (TTM)

$-2.00

P/E Ratio

-1.34

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$2.69

Volume

327,157.618

Open

$2.68

Previous Close

$2.69

Daily Range

$2.65 - $2.74

52-Week Range

$0.86 - $3.60

ABOS News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Acumen Pharmaceuticals

Industry

Biotechnology

Employees

61

CEO

Daniel J. O'Connell, MBA

Headquarters

Newton, VA 22902, US

ABOS Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-96%

Return on Capital

-1%

Return on Assets

-99%

Earnings Yield

-74.63%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$194.25M

Shares Outstanding

72.21M

Volume

327.16K

Short Interest

0.00%

Avg. Volume

893.20K

Financials (TTM)

Gross Profit

$184.00K

Operating Income

$123.83M

EBITDA

$123.83M

Operating Cash Flow

$115.54M

Capital Expenditure

$88.00K

Free Cash Flow

$115.63M

Cash & ST Invst.

$116.86M

Total Debt

$31.31M

Acumen Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$45.00K

-2.3%

Gross Margin

0.00%

N/A

Market Cap

$194.25M

N/A

Market Cap/Employee

$3.18M

N/A

Employees

61

N/A

Net Income

$25.14M

+32.3%

EBITDA

$25.11M

+30.4%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$85.55M

-39.7%

Accounts Receivable

$625.00K

N/A

Inventory

$0.00

-100.0%

Long Term Debt

$22.40M

-24.3%

Short Term Debt

$8.91M

+6603.0%

Return on Assets

-98.78%

N/A

Return on Invested Capital

-1.33%

N/A

Free Cash Flow

$19.10M

+29.8%

Operating Cash Flow

$19.10M

+29.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AGENAgenus Inc.
$4.64-3.93%
FATEFate Therapeutics, Inc.
$1.37+6.20%
SPROSpero Therapeutics, Inc.
$2.68+1.52%
SEERSeer, Inc.
$2.05+4.59%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.07-0.02%
INTCIntel
$68.50+0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$56.43+0.01%
HIMSHims & Hers Health
$26.99+0.11%

Questions About ABOS

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.